On Thursday, Scotiabank initiated coverage on shares of INmune Bio Inc. (NASDAQ:INMB) with a Sector Outperform rating and set a price target of $22.00. The bank’s analysis highlighted the potential of INmune Bio’s lead drug candidate, XPro, which is currently in clinical development for the treatment of Alzheimer’s disease (AD).
Scotiabank’s recommendation to buy shares of INmune Bio is based on what the bank describes as “compelling evidence” from medical literature and early clinical results. The firm suggests that XPro’s selective neutralization of soluble tumor necrosis factor (TNF), while not affecting membrane-bound TNF, could lead to a more favorable impact on neuroinflammation associated with Alzheimer’s disease, potentially improving disease outcomes.
The company is expected to release top-line results from a six-month Phase 2 trial of XPro in early Alzheimer’s patients in the second quarter of 2025. This timeline is contingent on the trial’s completion of enrollment by September 2024 and the absence of any unexpected serious safety concerns. Additionally, a first look at Phase 1 results for INmune Bio’s second pipeline candidate, INKmune, is anticipated in the fourth quarter of 2024.
Scotiabank also noted a slight concern regarding INmune Bio’s financing, pointing out the company’s limited cash runway into the first half of 2025. This financial aspect could pose an overhang on the company’s shares, according to the bank’s analysis. Despite this, the bank’s outlook on INmune Bio’s stock remains positive, given the potential of its lead drug candidate in the Alzheimer’s disease market.
In other recent news, INmune Bio Inc. reported significant progress in its INKmune memory-like natural killer cell oncology platform and its ongoing Phase II Alzheimer’s study during its second quarter 2024 earnings call.
The interim analysis of the Phase II trial of XPro in early Alzheimer’s disease showed encouraging results, with full enrollment expected by September. The company also reported a successful equity offering, raising approximately $14.5 million in gross proceeds, ensuring sufficient funds for operations until 2025.
Furthermore, INmune Bio published a paper highlighting the unique characteristics of memory-like natural killer cells generated by INKmune. The company anticipates patient-level data from the Phase I/II trial in castrate-resistant metastatic prostate cancer later this year. Moreover, a Phase II trial for treatment-resistant depression is slated to begin in the second half of 2024.
Moreover, INmune Bio executives, Mark Lowdell and Raymond Tesi, discussed the unique advantages of INKmune, including its cost-effectiveness and ease of shipping. The company also detailed the enrichment process for patient enrollment in the Phase II Alzheimer’s trial, focusing on patients with specific biomarkers. These are recent developments that underline INmune Bio’s commitment to advancing its clinical trials and bringing innovative treatments to the market.
InvestingPro Insights
As INmune Bio Inc. (NASDAQ:INMB) navigates the development of its lead drug candidate XPro, real-time data from InvestingPro provides a snapshot of the company’s financial health and market performance.
With a market capitalization of approximately $135.36 million and trading near its 52-week low, INmune Bio holds more cash than debt, which is a positive sign for investors concerned about the company’s financial stability. This is complemented by the fact that the company’s liquid assets exceed its short-term obligations, as per InvestingPro Tips, reflecting a degree of financial resilience.
However, analysts have flagged several challenges, including an anticipated sales decline and an expected drop in net income in the current year. The company is also not expected to be profitable this year, and the stock has experienced significant volatility and a notable decline over the last six months. Despite these concerns, Scotiabank’s coverage initiation suggests that the company’s clinical progress may offer long-term value, particularly if XPro shows positive outcomes in upcoming trial results.
Investors considering INmune Bio’s stock should be aware that the company does not pay dividends, which may influence the investment strategy for income-focused portfolios. For those seeking more comprehensive analysis, InvestingPro offers additional insights, with over 10 InvestingPro Tips available for INmune Bio, providing deeper context into the company’s performance and prospects in the challenging biotechnology industry.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.